Form 4: ACTUATE THERAPEUTICS Director Roger Sawhney Granted 15,000 Stock Options

Roger Sawhney, a Director at Actuate Therapeutics, Inc. (ACTU), was granted 15,000 stock options with an exercise price of $10.10 per share, vesting fully on the anniversary of the grant date.

Summary

• Roger Sawhney, a Director of ACTUATE THERAPEUTICS, INC. (ACTU), acquired 15,000 derivative securities in the form of stock options.
• The transaction date for this acquisition was May 22, 2025.
• Each stock option has an exercise price of $10.10.
• The options are scheduled to vest in full on the anniversary of the grant date, which is May 22, 2026.
• The expiration date for these stock options is May 22, 2035.
• Following this transaction, Roger Sawhney directly beneficially owns 15,000 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns management's interests with shareholders, incentivizing long-term performance. It's a standard compensation practice.

Positives

• The grant of stock options to Director Roger Sawhney aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a substantial window for potential value realization.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on an insider's equity transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common across all industries as a form of executive and director compensation, aiming to align management incentives with shareholder value creation. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as a positive for shareholders, as it aligns the director's financial interests with the company's long-term stock performance, potentially leading to increased shareholder value.

Next Steps

• The 15,000 stock options granted to Roger Sawhney are expected to vest in full on May 22, 2026.

Key Dates

Keywords

ACTUATE THERAPEUTICS, ACTU, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant